The Truth About What’s Failing in Longevity Science

The speaker emphasises that SGLT2 inhibitors started as diabetes drugs but were serendipitously repurposed for heart failure and kidney disease in non-diabetics, showing broad metabolic protection. The ITP's positive result with canloen (14% male lifespan extension) provides the solid reproducible evidence he demands. This positions SGLT2 inhibitors as a candidate for longevity use in the general population. He frames this as a high-upside, validated intervention worth investing time and research into.

The speaker notes that GLP-1 agonists have followed a trajectory similar to SGLT2 inhibitors: originally for diabetes, now repurposed for sleep apnoea, heart failure, and kidney disease. He highlights how the development of dual- and triple-agonist peptides (tirzepatide, retatrutide) is producing stepwise improvements in weight loss. This momentum and the solid foundational science make the class ripe for innovation and potentially for broader longevity applications. He frames it as an interesting hypothesis to test.

The speaker contrasts the old ablative approach—burning skin with significant recovery—with the new non-ablative wave that delivers almost as good results without downtime. He also highlights LED red light and IPL as emerging options for texture and pigmentation. He explicitly states that he personally uses these technologies and recommends them to patients, positioning them as accessible, evidence-based cosmetic interventions that align with the broader theme of validated, scalable science.

The speaker outlines a clear pattern: an exciting discovery emerges from one lab, massive investment follows, and years later the result cannot be replicated, leading to collapse. He draws a parallel with SpaceX's approach to landing rockets—embracing expected failures to learn and iterate—and argues longevity science should adopt the same mindset. Instead of chasing headlines, the field should demand multi-site replication before scaling. He proposes the Interventions Testing Program as the practical tool for this pre-validation step, ensuring that human studies are built on a solid reproducible rock.

The speaker explains that the ITP runs the same lifespan experiment simultaneously at three labs using genetically diverse mice. This built-in replication ensures a positive result is likely true. He contrasts the ITP's results with the earlier hype: fisetin, a senolytic candidate, showed no lifespan extension or other benefits in the ITP, indicating the preclinical senolytic work isn't ready to scale. Similarly, nicotinamide riboside (NR) produced no lifespan or other benefits, revealing that NAD metabolism support is not yet well understood enough. In contrast, the SGLT2 inhibitor canloen gave a 14% male lifespan extension, and rapamycin consistently yields 17-25% extension in both sexes, providing the solid reproducible foundation he advocates.

The speaker explains that standard PCSK9 inhibitors work by forcing the liver to express many LDL receptors, pulling LDL particles out of blood. The new small interfering PCSK9 inhibitors build on this mechanism but offer dramatically extended duration: one dose and at six months LDL levels are about 50% lower than baseline. This ease—twice a year—means patients are far more likely to adhere, which in turn could massively reduce cardiovascular disease. He explicitly links this to the central message: the science is solid, now it's about scaling and implementation.

The speaker notes that rapamycin dosing has been the major barrier; now that early safety data suggests no increase in infections with proper dosing, they designed a study to test rapamycin with exercise in older adults, comparing an exercise+rapamycin group to exercise alone. He presents the fact that the study has concluded and been submitted for peer review as a significant step forward, hinting that the results give an interesting direction for healthy aging interventions. He invites listeners to find him after the talk to hear the details, indicating the findings are not yet public.